Literature DB >> 17621514

Kidney stones and the ketogenic diet: risk factors and prevention.

Amitha Sampath1, Eric H Kossoff, Susan L Furth, Paula L Pyzik, Eileen P G Vining.   

Abstract

A cohort study was performed of children started on the ketogenic diet for intractable epilepsy from 2000 to 2005 (n = 195). Children who developed kidney stones were compared with those without in terms of demographics, urine laboratory markers, and intervention with urine alkalinization (potassium citrate). Thirteen children (6.7%) developed kidney stones. The use of oral potassium citrate significantly decreased the prevalence of stones (3.2% vs 10.0%, P = .049) and increased the mean time on the ketogenic diet before a stone was first noted (260 vs 149 patient-months, P = .29). The prevalence of kidney stones did not correlate with younger age or use of carbonic anhydrate inhibitors (eg, topiramate or zonisamide) but trended toward higher correlation with the presence of hypercalciuria (92% vs 71%, P = .08). No child stopped the diet due to stones; in fact, the total diet duration was longer (median 26 vs 12 months, P < .001). Kidney stones continue to occur in approximately 1 in 20 children on the ketogenic diet, and no statistically significant risk factors were identified in this cohort. As oral potassium citrate was preventative, prospective studies using this medication empirically are warranted.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17621514     DOI: 10.1177/0883073807301926

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  34 in total

1.  Purines and the Anti-Epileptic Actions of Ketogenic Diets.

Authors:  Susan A Masino; Masahito Kawamura; David N Ruskin; Jeremy Gawryluk; Xuesong Chen; Jonathan D Geiger
Journal:  Open Neurosci J       Date:  2010-01-01

Review 2.  Pediatric urolithiasis: causative factors, diagnosis and medical management.

Authors:  Funda Baştuğ; Ruhan Düşünsel
Journal:  Nat Rev Urol       Date:  2012-02-07       Impact factor: 14.432

3.  Treating epilepsy in the setting of medical comorbidities.

Authors:  Nivedita U Jerath; Dronacharya Lamichhane; Madhu Jasti; Vinusha Yarlagadda; Eduardo Zilli; Yara Nazzal; Mark Granner
Journal:  Curr Treat Options Neurol       Date:  2014-07       Impact factor: 3.598

4.  Ketotic hypercalcemia: a case series and description of a novel entity.

Authors:  Colin Patrick Hawkes; Michael A Levine
Journal:  J Clin Endocrinol Metab       Date:  2014-02-25       Impact factor: 5.958

Review 5.  Pediatric stone disease.

Authors:  Stacy T Tanaka; John C Pope
Journal:  Curr Urol Rep       Date:  2009-03       Impact factor: 3.092

6.  Trends in pediatric urolithiasis: patient characteristics, associated diagnoses, and financial burden.

Authors:  Kirsten Kusumi; Brian Becknell; Andrew Schwaderer
Journal:  Pediatr Nephrol       Date:  2014-12-07       Impact factor: 3.714

7.  Hypercalcemia in Children Using the Ketogenic Diet: A Multicenter Study.

Authors:  Colin P Hawkes; Sani M Roy; Bassem Dekelbab; Britney Frazier; Monica Grover; Jaime Haidet; James Listman; Sarianne Madsen; Marian Roan; Celia Rodd; Aviva Sopher; Peter Tebben; Michael A Levine
Journal:  J Clin Endocrinol Metab       Date:  2021-01-23       Impact factor: 5.958

Review 8.  Drug-Induced Urolithiasis in Pediatric Patients.

Authors:  Maria Chiara Sighinolfi; Ahmed Eissa; Luigi Bevilacqua; Ahmed Zoeir; Silvia Ciarlariello; Elena Morini; Stefano Puliatti; Viviana Durante; Pier Luca Ceccarelli; Salvatore Micali; Giampaolo Bianchi; Bernardo Rocco
Journal:  Paediatr Drugs       Date:  2019-10       Impact factor: 3.022

9.  Adenosine, ketogenic diet and epilepsy: the emerging therapeutic relationship between metabolism and brain activity.

Authors:  S A Masino; M Kawamura; C D Wasser; C A Wasser; L T Pomeroy; D N Ruskin
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

Review 10.  Ketogenic ratio, calories, and fluids: do they matter?

Authors:  Elaine C Wirrell
Journal:  Epilepsia       Date:  2008-11       Impact factor: 5.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.